Cardiovascular Disease

Panel recommends values for Lp-PLA2 in assessment of cardiovascular disease risk

Published in Heart Disease Weekly, September 3rd, 2006

diaDexus, Inc. announced the publication of the first recommendations for a proposed cut point for lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that independently predicts the risk of coronary heart disease and ischemic stroke.

The report was published in the Summer 2006 issue of Preventive Cardiology.

The paper proposes that clinical laboratories set greater than or equal to 235 ng/mL (the median value of the samples analyzed in this study) as the Lp-PLA2 concentration decision value to be used to decide whether patients should be moved to a higher cardiovascular risk category. This cut point is not proposed as a treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Heart Disease Weekly

Source: Heart Disease Weekly (2006-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry